MedKoo Cat#: 407046 | Name: BI-4020

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BI-4020 is a highly active, non-covalent EGFR inhibitor (IC50 = 0.6 nM). BI-4020 displays a single digit-nanomolar antiproliferative activity against EGFR mutant dependent cells, including cells which are dependent on EGFR bearing the two most clinically prevalent resistance mutations T790M and C797S. At the same time BI-4020 shows a sufficient EGFRwt sparing window and high kinome selectivity that is comparable to the one observed with osimertinib. Furthermore BI-4020 induces tumor regressions in the osimertinib resistant PC-9 (EGFRdel19 T790M C797S) triple mutant mouse xenograft model.

Chemical Structure

BI-4020
BI-4020
CAS#Unknown

Theoretical Analysis

MedKoo Cat#: 407046

Name: BI-4020

CAS#: Unknown

Chemical Formula: C30H38N8O2

Exact Mass: 542.3118

Molecular Weight: 542.69

Elemental Analysis: C, 66.40; H, 7.06; N, 20.65; O, 5.90

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
BI-4020; BI 4020; BI4020;
IUPAC/Chemical Name
(R,E)-11,26,7-trimethyl-56-((4-methylpiperazin-1-yl)methyl)-52,53-dihydro-11H,51H-11-oxa-4-aza-5(2,1)-benzo[d]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one
InChi Key
AIQBYZOTCIQTGW-HXUWFJFHSA-N
InChi Code
InChI=1S/C30H38N8O2/c1-20-6-5-13-40-29-24(17-31-36(29)4)26-16-23(14-21(2)32-26)28(39)34-30-33-25-8-7-22(15-27(25)38(30)18-20)19-37-11-9-35(3)10-12-37/h7-8,14-17,20H,5-6,9-13,18-19H2,1-4H3,(H,33,34,39)/t20-/m1/s1
SMILES Code
O=C1C2=CC(C3=C(N(N=C3)C)OCCC[C@H](CN(C4=CC(CN5CCN(CC5)C)=CC=C4N/6)C6=N\1)C)=NC(C)=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 542.69 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Start selective and rigidify: The discovery path towards a next generation of EGFR tyrosine kinase inhibitors. Harald EngelhardtDietrich BöseMark PetronczkiDirk ScharnGerd BaderAnke BaumAndreas BergnerEugene ChongSandra DöbelGeorg EggerChristian EngelhardtPeter EttmayerJulian E. FuchsThomas GerstbergerNina C. GonnellaAndreas GrimmElisabeth GrondalNizar HaddadBarbara HopfgartnerRoland KousekMariusz KrawiecMonika KrizLyne LamarreJoyce LeungMoriz MayerNitinchandra D PatelBiljana Peric SimovJonathan T. ReevesRenate SchnitzerAndreas SchrenkBernadette SharpsFlavio SolcaHeinz StadtmüllerZhulin TanTobias WunbergAndreas ZöphelDarryl B. McConnell Journal of Medicinal Chemistry, Just AcceptedSubscribed Access Publication Date (Web):November 5, 2019 DOI: 10.1021/acs.jmedchem.9b01169